Christine Ibilibor, MD, discusses 6 noteworthy abstracts from the 2022 Genitourinary Cancers Symposium.
In this video, Urology Times® Editorial Council member Christine Ibilbor, MD, discusses abstracts on metastatic urothelial carcinoma, renal cell carcinoma, and rare cancers that will be presented at the 2022 Genitourinary Cancers Symposium. Ibilibor is an assistant professor of urology at the University of Virginia in Charlottesville.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.